Genetic and Nongenetic Implications of Racial Variation in Response to Antiplatelet Therapy.
Journal
The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277
Informations de publication
Date de publication:
01 06 2019
01 06 2019
Historique:
received:
30
11
2018
revised:
18
02
2019
accepted:
20
02
2019
pubmed:
11
4
2019
medline:
30
1
2020
entrez:
11
4
2019
Statut:
ppublish
Résumé
Race has been identified as an independent risk factor for poor prognosis and an independent predictor of survival in coronary artery disease. Race-related dissimilarities have been identified in cardiovascular patients in terms of age of presentation, co-morbidities, socioeconomic status, and treatment approach as well as genetically driven race-related disparities in responsiveness to medications. Antiplatelet therapy represents a fundamental component of therapy in cardiovascular patients, especially in patients presenting with acute coronary syndromes. It has been argued that the different level of platelet reactivity and varying response to antiplatelet therapy among races may account in part for worse outcomes in certain populations. The purpose of this review is to describe genotypic and phenotypic race-related differences in platelet reactivity and responsiveness to cardiovascular treatment, focusing on antiplatelet therapy to highlight the need establish a more effective and targeted antithrombotic strategy.
Identifiants
pubmed: 30967284
pii: S0002-9149(19)30292-9
doi: 10.1016/j.amjcard.2019.02.047
pii:
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1878-1883Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.